A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

<p>Abstract</p> <p>Background</p> <p>The sole effective option for patients with advanced HCC is sorafenib and there is an urgent need to develop new therapeutic approaches. Immunotherapy is a promising option that deserves major investigation. In this open label, singl...

Full description

Bibliographic Details
Main Authors: Ayuso Carmen, Barget Nathalie, N'Kontchou Gisele, Korangy Firouzeh, Forner Alejandro, Greten Tim F, Ormandy Lars A, Manns Michael P, Beaugrand Michel, Bruix Jordi
Format: Article
Language:English
Published: BMC 2010-05-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/10/209

Internet

http://www.biomedcentral.com/1471-2407/10/209

Similar Items